Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MANDARA: Benralizumab vs Mepolizumab in EGPA
NCT04157348Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2019
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of benralizumab in eosinophilic granulomatosis with polyangiitis (EGPA), sponsored by AstraZeneca. Started Oct 2019; status: active, not recruiting.
02
Drugs
benralizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on NCT04157348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04157348.